News
PRONOVA PARTNERS WITH HHTC TO ENHANCE SC360 WITH SUPERCONDUCTING CYCLOTRON
June 6, 2024, Maryville, Tennessee, USA
ProNova Solutions, LLC, (ProNova) a US medical device manufacturer committed
to revolutionizing oncology solutions with the most advanced proton therapy
system in the world, and Holistic Health Technology Corporation (HHTC), a
private equity firm with a focus on cancer related innovations announce today
that they have entered into a strategic partnership, pursuant to which ProNova
Solutions will develop and launch the Superconducting Isochronous Cyclotron
(SCIC) for commercialization as an integral component of the SC360 proton
therapy system.
Sharing a
vision to make proton therapy more accessible to cancer patients worldwide,
HHTC and ProNova are collaborating to develop an ultra-compact,
high-performance, and economically efficient proton therapy system. This partnership leverages ProNova’s
innovative proton treatment technology and HHTC’s expertise in finance and
supply chain management for precision machining and semiconductor
manufacturing.
"HHTC
and ProNova are aligned
in their mission and purpose to enhance the health and welfare of cancer
patients," said Alex Lin, Founder and CEO of HHTC. "We are thrilled
to collaborate with ProNova. By combining our strengths in R&D, capital
resources, affiliated proton treatment centers and high-tech industries such as
semiconductor manufacturing, artificial intelligence, and precision machining,
we aim to support ProNova in their mission to expand proton therapy use around
the world."
The ProNova SC360
has successfully treated over 2,000 patients with three treatment rooms at the Tennessee Oncology Proton Center in Nashville, TN, USA. The SCIC will be
integrated into the FDA-approved and clinically demonstrated ProNova SC360 to provide up to a 1000 nA high-current beam, that supports rapid
hypofractionation, breath-hold treatments and clinical FLASH deliveries. The patient-centric SC360 will offer an
improved and distinguished comprehensive proton therapy system, infused with the latest AI-empowered capabilities, including the SCIC cyclotron and a 360o
superconducting gantry capable of Arc therapy.
“The SC360 is a major breakthrough in our fight against cancer and out-delivers
any other proton therapy system in the world, with precise, on-demand dosage
treatments, less collateral damage, higher operational efficiencies and
clinical value,” says Moataz Karmalawy, President, and CEO of ProNova Solutions.
About ProNova
Solutions, LLC
ProNova Solutions, a US medical device manufacturer and subsidiary of Provision Healthcare, was founded in 2011, to create the most innovative proton therapy technology without compromise to the patient.
About Holistic Health
Technology Corporation
HHTC’s mission is to contribute to a comprehensive portfolio of cutting-edge cancer screening technology, particle therapy, and regenerative medicine (the “H2Solutions”).
Contacts:
Nancy Howard, ProNova
Solutions: Email
James Lin, HHTC: Email
ProNova Solutions Announces Moataz Karmalawy as President/CEO to Advance Proton Therapy thru Global Development and Partnerships
February 26, 2024, Maryville, Tennessee, USA
Dr. Moataz Karmalawy has been named President & Chief Executive Officer of ProNova Solutions, LLC, and Senior Vice President of Provision Healthcare, LLC, the parent company of ProNova. Karmalawy will provide strategic business knowhow to improve proton therapy outcomes using ProNova’s state-of-the art proton therapy solutions through the development of innovative relationships in proton therapy centers and comprehensive cancer care centers. Most recently, Moataz has been the President of Advanced Oncotherapy. Prior to that, and for 12 years, he served as the President of the Worldwide Particle Therapy business at Varian Medical Systems which was acquired by Siemens. Prior to joining Varian, Moataz worked for ADAC/Philips Medical Systems for 10 years in a variety of roles including Vice President of Research and Development, Vice President of Operations and Vice President of Strategic Development. Karmalawy’s globally respected leadership, experience, entrepreneurial contributions, and knowhow in the healthcare industry will accelerate the mission and success of ProNova Solutions and Provision Healthcare.
“We are excited that Moataz chose to join our organization and continue our mission to improve patient access to proton therapy and advanced cancer care,” says Terry Douglass, Ph.D., Provision Healthcare and ProNova Chairman & Founder. “We know Moataz will bring incredible experience and knowhow to this role, and we are confident he will serve as a thought leader for our team and the radiation therapy and advanced cancer care industry as well. Our team looks forward to working with Moataz as our new ProNova President/CEO.”
About ProNova
ProNova Solutions, LLC, a subsidiary of Provision Healthcare, is committed to making proton therapy accessible to a greater number of patients and physicians worldwide. ProNova was founded by former leaders of CTI Molecular Imaging, which brought positron emission tomography (PET) technology out of the laboratory and made it a clinical reality for millions of cancer patients. Today the same team continues redefining cancer treatment with the SC360, the only superconducting 360-degree compact proton therapy system. It is the only proton therapy system developed in a clinical setting, benefiting from continuous input from physicians, medical physicists, and therapists during design and development. The system includes state of the-the art features such as pencil beam scanning and advanced imaging with cone-beam CT, all in a compact design.
About Provision Healthcare
Provision Healthcare LLC was formed in 2005 with the purpose of developing innovative healthcare solutions focused on improving patient care and clinical outcomes and developing support for research and education. Provision has developed a unique, comprehensive expertise in proton therapy and healthcare solutions, including Provision’s patient-focused “Culture of Care” that distinguishes Provision from other proton and cancer center developers and operators that have a much narrower focus. The combination of unique expertise and an innovative entrepreneurial approach continues to propel Provision towards a position of industry leadership with respect to both cancer care and proton therapy.
Media Contact: Nancy Howard , VP Marketing, Provision Healthcare
Phone 865-603-0865
Email nancy.howard@provisionhealthcare.com
Web link www.pronovasolutions.com